As the immunomodulatory cells play a pivotal role orchestrating the immunofibrotic niche within the lung, we next sought to investigate whether the alleviation in pulmonary fibrosis following SHP-1 agonist treatment was a result of altered immune cell population. The gene discussed is PTPN6; the disease is pulmonary fibrosis.